Mechanisms of action of the anti-cancer organic arsenical darinaparsin - Garnier, Nicolas
36,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Arsenic trioxide (ATO) is a successful treatment for Acute Promyelocytic Leukemia (APL), but other cancers remain mildly sensitive to ATO at clinically achievable doses. Moreover, APL cells can develop resistance to ATO. Darinaparsin (S-dimethylarsino-GSH; Dar) is a more potent apoptosis-inducing arsenical than ATO in various cancer models. It also has a maximum tolerated dose that is 35-fold higher than ATO. Dar accumulates in the cell to a greater extent that ATO, which led to hypothesize that Dar import might contribute to its enhanced efficacy. We found that Dar gets transformed…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Arsenic trioxide (ATO) is a successful treatment for Acute Promyelocytic Leukemia (APL), but other cancers remain mildly sensitive to ATO at clinically achievable doses. Moreover, APL cells can develop resistance to ATO. Darinaparsin (S-dimethylarsino-GSH; Dar) is a more potent apoptosis-inducing arsenical than ATO in various cancer models. It also has a maximum tolerated dose that is 35-fold higher than ATO. Dar accumulates in the cell to a greater extent that ATO, which led to hypothesize that Dar import might contribute to its enhanced efficacy. We found that Dar gets transformed extracellularly and imported via cystine/cysteine importing systems. We also hypothesized that the increased cytotoxicity of Dar may be due to a decreased cytoprotective response. We found that a lack of HO-1 activation is partially responsible for Dar's enhanced anti-tumor properties. Cells respond to arsenicals by increasing cystine uptake and HO-1 expression, which leads to protection against ATO but hypersensitivity to Dar. This work encompasses many aspects of modern molecular pharmacology, experimental oncology, and should inspire future efforts towards designing arsenic-based anti-cancer drugs.
Autorenporträt
Dr. Nicolas Garnier is currently working on pharmacogenomics at the CHU Sainte-Justine Research Center, Montreal, Canada. He has completed his M. Sc. in Cellular Biology, Physiology, Pathology & Genetics in 2008 at Paris 7 University, France, and his Ph.D degree in Experimental Medicine in 2013 at McGill University, Montreal, Canada.